About glofitamab
Bispecific CD20×CD3 monoclonal antibody
Used for
- Treats adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments.
Usual adult dose
Intravenous step-up dosing: 2.5 mg on day 1, 10 mg on day 8, then 30 mg every 21 days; usually up to 12 cycles. Obinutuzumab pretreatment is required.
Common side effects
- Cytokine release syndrome
- Low blood-cell counts
- Fever and fatigue
- Infections
Important warnings
- Can cause serious, potentially life-threatening cytokine release syndrome.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity, can occur.
- Treatment requires specialist supervision and monitoring, especially during step-up doses.
- May cause serious infections and tumor lysis syndrome.
Pregnancy
May harm an unborn baby; pregnancy status should be assessed before treatment. Effective contraception is recommended during treatment and for three months afterward.
Breastfeeding
Do not breastfeed during treatment and for three months after the final dose.
Interactions
- Other medicines that affect immune function may increase treatment-related risks.
- Live vaccines should be avoided during treatment and until immune recovery.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.